Assessing Healthcare Resource Use and Burden Among an Older Population of Patients With Respiratory Syncytial Virus in Five European Countries Using Real-World Data

Speaker(s)

Mendes D1, Hughes M2, Quiñones E2, Li K2, Fiévez S3, Lade C4, Di Virgilio R5, López A6, Butfield R7, Hennessy F2, Holbrook T2, Sato R8
1Pfizer Ltd., Tadworth, SRY, UK, 2Adelphi Real World, Bollington, Cheshire, UK, 3Pfizer France, Paris, France, 4Pfizer Pharma GmbH, Berlin, Berlin, Germany, 5Pfizer Italia Srl, Rome, Rome, Italy, 6Health Economics and Outcomes Research,Pfizer S.L.U., Alcobendas, Madrid, Spain, 7Pfizer Ltd., Tadworth, Surrey, UK, 8Pfizer Inc., Collegeville, PA, USA

Presentation Documents

OBJECTIVES: To characterise resource use and economic burden among older adults with Respiratory Syncytial Virus (RSV) in France, Germany, Italy, Spain and the United Kingdom.

METHODS: Data were obtained from the Adelphi RSV Disease Specific Programme™, a cross-sectional survey with retrospective elements collected between December 2023-May 2024. Healthcare professionals (HCPs) provided data on health- and social-care resource utilisation (HCRU, SCRU) for their next four consecutively consulting older adult (≥60 years) patients with an RSV diagnosis confirmed using molecular testing, consisting of three groups: initial infection, primary care (I-RSV); long-RSV (symptoms ≥12 weeks; L-RSV); hospitalised, secondary care (H-RSV). Data were analysed descriptively.

RESULTS: HCPs (n=1081) provided data for 2355 patients (mean [standard deviation; SD] age: 73 years [8.35]; 52.1% [n=1226] male).

Patients ever hospitalised for RSV in the I-RSV (7.6% [n=60]), L-RSV (13.6% [n=100]), and H-RSV (100% [n=836]) groups spent a mean (SD) of 7.5 (7.62 [n=38]), 9.1 (7.78 [n=75]) and 7.7 (5.83 [n=555]) nights in hospital, respectively, where this was known. Most H-RSV patients were admitted through the emergency room (82.8% [n=523]), 68.9% (n=576) received oxygen/intravenous fluids, and 14.9% (n=94) were admitted to the intensive care unit (ICU), staying on average 3.3 (SD: 2.09) nights in ICU. Over two-fifths of patients (I-RSV: 35.2% [n=276]; L-RSV: 40.1% [n=294]; H-RSV: 47.2% [n=395]) had received treatment for their RSV, of whom two thirds were prescribed ribavirin (I-RSV: 65.2% (n=92); L-RSV: 73.2% (n=104); H-RSV: 62.5% (n=167)).

HCPs reported that 36.1% (n=283), 41.6% (n=305) and 48.1% (n=402) of I-RSV, L-RSV and H-RSV patients received caregiver support, often from family/friends (I-RSV: 28.5% [n=224]; L-RSV: 32.7% [n=240]; H-RSV: 37.6% [n=314]) or professional caregivers (I-RSV:7.4% [n=58]; L-RSV: 10.6% [n=78]; H-RSV: 13.8% [n=115]).

CONCLUSIONS: Results suggest considerable HCRU and SCRU among European patients with RSV associated to substantial economic burden for both patients and healthcare systems.

Code

EE722

Topic

Economic Evaluation

Disease

Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas